Next Science Ltd (ASX: NXS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Next Science Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Next Science Ltd (ASX: NXS)
Latest News
Share Gainers
Why ANZ, Next Science, Macmahon, and Pointsbet shares are racing higher
Healthcare Shares
Guess which ASX healthcare share is booming 28% on a sales boost
Healthcare Shares
Next Science shares defy ASX market slump to surge 8%
Healthcare Shares
Here's why the Next Science (ASX:NXS) share price is rocketing 11% today
Healthcare Shares
What happened to the Next Science (ASX:NXS) share price last earnings season?
Share Gainers
Next Science (ASX:NXS) share price jumps on record revenue growth
Technology Shares
Next Science (ASX:NXS) share price swings on lowered earnings update
Healthcare Shares
Here's why the Next Science (ASX:NXS) share price finished higher today
Healthcare Shares
Next Science (ASX:NXS) share price falls despite 'exciting future ahead'
Share Gainers
Why Doctor Care Anywhere, Next Science, NIB, & Talga are charging higher
Healthcare Shares
Why the Next Science (ASX:NXS) share price opened 40% higher
Share Fallers
Why Alumina, Delorean, Next Science, & Pushpay shares are tumbling lower
NXS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Next Science Ltd
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
NXS Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
11 Dec 2024 | $0.12 | $-0.01 | -8.00% | 272,802 | $0.13 | $0.13 | $0.12 |
10 Dec 2024 | $0.13 | $-0.01 | -7.41% | 142,288 | $0.14 | $0.14 | $0.13 |
09 Dec 2024 | $0.14 | $0.00 | 0.00% | 50,172 | $0.13 | $0.14 | $0.13 |
06 Dec 2024 | $0.14 | $-0.01 | -6.90% | 98,765 | $0.13 | $0.14 | $0.13 |
05 Dec 2024 | $0.15 | $0.01 | 7.41% | 172,334 | $0.14 | $0.15 | $0.14 |
04 Dec 2024 | $0.14 | $0.01 | 7.69% | 9,964 | $0.14 | $0.14 | $0.13 |
03 Dec 2024 | $0.13 | $-0.01 | -7.14% | 222,057 | $0.14 | $0.14 | $0.13 |
02 Dec 2024 | $0.14 | $0.01 | 7.69% | 45,534 | $0.13 | $0.14 | $0.13 |
29 Nov 2024 | $0.13 | $-0.01 | -7.41% | 189,740 | $0.14 | $0.14 | $0.13 |
28 Nov 2024 | $0.14 | $-0.01 | -7.14% | 143,423 | $0.14 | $0.14 | $0.14 |
27 Nov 2024 | $0.14 | $0.00 | 0.00% | 366,230 | $0.14 | $0.14 | $0.14 |
26 Nov 2024 | $0.15 | $0.01 | 7.41% | 4,887 | $0.14 | $0.15 | $0.14 |
25 Nov 2024 | $0.14 | $0.00 | 0.00% | 199,740 | $0.14 | $0.14 | $0.14 |
22 Nov 2024 | $0.14 | $-0.01 | -7.02% | 10,699 | $0.14 | $0.14 | $0.14 |
21 Nov 2024 | $0.14 | $0.01 | 7.41% | 44,115 | $0.14 | $0.14 | $0.14 |
20 Nov 2024 | $0.14 | $-0.01 | -7.14% | 158,157 | $0.15 | $0.15 | $0.14 |
19 Nov 2024 | $0.14 | $0.00 | 0.00% | 215,487 | $0.14 | $0.15 | $0.14 |
18 Nov 2024 | $0.15 | $0.01 | 7.41% | 257,483 | $0.14 | $0.15 | $0.14 |
15 Nov 2024 | $0.14 | $-0.02 | -13.33% | 836,211 | $0.16 | $0.16 | $0.14 |
14 Nov 2024 | $0.15 | $0.01 | 7.14% | 238,584 | $0.15 | $0.16 | $0.15 |
13 Nov 2024 | $0.14 | $-0.01 | -6.67% | 401,318 | $0.15 | $0.16 | $0.14 |
12 Nov 2024 | $0.15 | $0.01 | 6.90% | 396,121 | $0.16 | $0.16 | $0.14 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
16 Sep 2024 | Harry Hall(IV) | Issued | 3,361,855 | $450,000 |
Issue of options. usd$
|
16 Sep 2024 | Harry Hall(IV) | Issued | 1,814,394 | $450,000 |
Issue of securities. usd$, 2,744,656 Rights
|
26 Jul 2024 | Harry Hall(IV) | Exercise | 465,131 | $127,911 |
Conversion of securities. 930,262 Rights
|
26 Jul 2024 | Harry Hall(IV) | Issued | 465,131 | $127,911 |
Conversion of securities.
|
14 Jun 2024 | Harry Hall(IV) | Issued | 1,395,393 | $348,848 |
Issue of securities. 1,395,393 Sign-on Rights
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Grant Hummel | Non-Executive Director | Aug 2023 |
Mr Hummel was part of Next Science's ASX listing deal team in 2019. He has been a partner of a major Australian law firm, for over fifteen years. Grant has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients.
|
Ms Aileen Stockburger | Non-Executive DirectorNon-Executive Chairman | Oct 2018 |
Mr Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Aileen led Johnson & Johnson's efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson's medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He held dirctorships in Microbot Medical Inc. as Non Executive Director from last 3 years. He is Member of Risk, People & Culture Committee.
|
Ms Katherine (Kathy) Ostin | Non-Executive Director | Oct 2023 |
Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in aged care and healthcare sectors, having established and led KPMG's New South Wales Health, Ageing and Human Services audit practice from 2006 to 2017. During her 24 years with KPMG, Kathy worked in Australia, the US, Asia, and the UK. She is Chair of Risk Committee.
|
Mr Harry Thomas Hall(IV) | Chief Executive OfficerManaging Director | Jul 2023 |
Mr Hall has more than 28 years' experience in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. Prior to joining Next Science, He was a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes, a subsidiary of Johnson and Johnson (NYSE:JNJ), and completed the launch of the first surgical robot developed by JNJ / DePuy Synthes. He joined DePuy Synthes in 1997 where he held senior roles including Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, He was responsible for a global portfolio and execution strategy for a US$3.2bn platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, He created and sustained personal relationships with well over one hundred key opinion leaders worldwide.
|
Ms Gillian Maria Nairn | Company Secretary | Jun 2018 |
-
|
Gillian Maria Nairn | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Hsbc Custody Nominees (Australia) Limited | 59,990,423 | 20.57% |
Auckland Trust Company Ltd <Second Pacific Master Superannuation Fund> | 56,019,938 | 19.20% |
Ubs Nominees Pty Ltd | 16,528,388 | 5.67% |
Hsbc Custody Nominees (Australia) Limited A/C 2 | 11,839,023 | 4.06% |
Mr Charles Robert Dirck Wittenoom | 5,118,880 | 1.75% |
Judith Lee Mitchell | 4,706,975 | 1.61% |
Dr Matthew Franco Myntti | 4,171,824 | 1.43% |
Citicorp Nominees Pty Limited | 3,815,931 | 1.31% |
Mr James Fong Seeto | 3,000,000 | 1.03% |
Bnpp Noms Pty Ltd Hub24 Custodial Serv Ltd | 2,925,007 | 1.00% |
J P Morgan Nominees Australia Pty Limited | 2,921,688 | 1.00% |
S G Andrew Pty Ltd <S G Andrew Super Fund A/C> | 2,745,000 | 0.94% |
Mr Dean Anthony Mackenzie | 2,514,258 | 0.86% |
Bond Street Custodians Limited <Lam1 D08047 A/C> | 2,460,427 | 0.84% |
Mr Evan Philip Clucas & Ms Leanne Jane Weston<Kuranga Nursery Super A/C> | 2,251,187 | 0.77% |
Belgravia Strategic Equities Pty Ltd | 1,965,000 | 0.67% |
Twenty Fifth Elporto Pty Ltd <Twenty Fifth Elporto Sf A/C> | 1,800,000 | 0.62% |
Brook St Smsf Pty Ltd <Brook St Smsf A/C> | 1,255,702 | 0.43% |
Retzos Executive Pty Ltd <Retzos Executive S/Fund A/C> | 1,057,146 | 0.36% |
Mr Timothy Ian Douglas | 1,032,075 | 0.35% |